Magainin Pharmaceuticals Inc. announced late Tuesday that it will proceed with plannedPhase IIB/III clinical trials on MSI-78 with the FDA. In those trials, MSI-78, fortreating impetigo, a serious skin infection that usually affects children. The firstpivotal trial should begin this summer.

The Plymouth Meeting, Pa. company (NASDAQ:MAGN) has reviewed the results of itscompleted Phase II clinical trial on MSI-78 with the FDA. In those trials, MSI-78, atopical broad spectrum antibiotic, produced a significant dose and frequency responseagainst a variety of bacteria inoculated on the are of 45 volunteers, the company said.

Magainin will present these results at the 33rd InterScience Conference onAntimicrobial Agents and Chemotherapy in October.

No Comments